Repository logo
 
Publication

Transforming cancer treatment: the potential of nanonutraceuticals

2024-12Journal article Open access
Simple item page
dc.contributor.authorKumar, Girish
dc.contributor.authorVirmani, Tarun
dc.contributor.authorChhabra, Vaishnavi
dc.contributor.authorVirmani, Reshu
dc.contributor.authorPathak, Kamla
dc.contributor.authorAkhtar, Md Sayeed
dc.contributor.authorAsim, Mulazim Hussain
dc.contributor.authorArshad, Shumaila
dc.contributor.authorSiddique, Farzana
dc.contributor.authorFonte, Pedro
dc.date.accessioned2024-12-27T20:18:31Z
dc.date.available2024-12-27T20:18:31Z
dc.date.issued2024-12
dc.description.abstractChemotherapy in the management of cancer is constrained by limitations like off-target effects, poor bioavailability, and dose-dependent toxicity. Nutraceuticals have been explored as an innovative strategy to overcome chemotherapy drawbacks. However, the clinical utility of nutraceuticals is restricted due to their complex structures, less water solubility, reduced stability, decreased bioavailability and more obstacles in the gastrointestinal tract. Nanonutraceuticals are nanosized nutraceutical particles having enhanced solubility, improved bioavailability, stability, and targeted delivery to specific cells. Nutraceuticals can be co-delivered with other chemotherapeutic drugs in nanocarriers to elicit synergistic effects. The targeting of nutraceuticals against cancer cells can be enabled by coupling ligands with the nanocarriers, which direct to the overexpressed receptors found at the surface of the cancer cells. Transitioning a nanonutraceutical from pre-clinical research to clinical trials is a pivotal step. This focus on advancing their application holds great potential for impacting clinical research and improving the treatment landscape for cancer patients. This review focuses on the role of nutraceuticals for cancer treatment, various nanocarriers for the efficient delivery of nutraceuticals along with co-administration of nutraceuticals with chemotherapeutic drugs using nanocarriers. Also, emphasize the targeting of ligands coupled nanocarriers to the cancer cells along with patents and clinical trials for nanonutraceuticals.eng
dc.description.sponsorshipRGP2/317/45
dc.identifier.doi10.1016/j.ijpharm.2024.124919
dc.identifier.issn0378-5173
dc.identifier.urihttp://hdl.handle.net/10400.1/26544
dc.language.isoeng
dc.peerreviewedyes
dc.publisherElsevier
dc.relationAlgarve Centre for Marine Sciences
dc.relationAlgarve Centre for Marine Sciences
dc.relationCentre for Marine and Environmental Research
dc.relationInstitute for Bioengineering and Biosciences
dc.relationInstitute for Bioengineering and Biosciences
dc.relationInstitute for Health and Bioeconomy
dc.relation.ispartofInternational Journal of Pharmaceutics
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/4.0/
dc.subjectNutraceuticals
dc.subjectCancer
dc.subjectNanonutraceuticals
dc.subjectLigands
dc.subjectNanocarrier
dc.subjectList of chemical compounds
dc.subjectCurcumin
dc.subjectQuercetin
dc.subjectSilymarin
dc.subjectEpigallocatechin gallate
dc.subjectCoenzyme Q
dc.subjectEllagic acid
dc.subjectBeta-carotene
dc.titleTransforming cancer treatment: the potential of nanonutraceuticalseng
dc.typejournal article
dspace.entity.typePublication
oaire.awardTitleAlgarve Centre for Marine Sciences
oaire.awardTitleAlgarve Centre for Marine Sciences
oaire.awardTitleCentre for Marine and Environmental Research
oaire.awardTitleInstitute for Bioengineering and Biosciences
oaire.awardTitleInstitute for Bioengineering and Biosciences
oaire.awardTitleInstitute for Health and Bioeconomy
oaire.awardURIinfo:eu-repo/grantAgreement/FCT/6817 - DCRRNI ID/UIDB%2F04326%2F2020/PT
oaire.awardURIinfo:eu-repo/grantAgreement/FCT/6817 - DCRRNI ID/UIDP%2F04326%2F2020/PT
oaire.awardURIinfo:eu-repo/grantAgreement/FCT/6817 - DCRRNI ID/LA%2FP%2F0101%2F2020/PT
oaire.awardURIinfo:eu-repo/grantAgreement/FCT/6817 - DCRRNI ID/UIDB%2F04565%2F2020/PT
oaire.awardURIinfo:eu-repo/grantAgreement/FCT/6817 - DCRRNI ID/UIDP%2F04565%2F2020/PT
oaire.awardURIinfo:eu-repo/grantAgreement/FCT/6817 - DCRRNI ID/LA%2FP%2F0140%2F2020/PT
oaire.citation.startPage124919
oaire.citation.titleInternational Journal of Pharmaceutics
oaire.citation.volume667
oaire.fundingStream6817 - DCRRNI ID
oaire.fundingStream6817 - DCRRNI ID
oaire.fundingStream6817 - DCRRNI ID
oaire.fundingStream6817 - DCRRNI ID
oaire.fundingStream6817 - DCRRNI ID
oaire.fundingStream6817 - DCRRNI ID
oaire.versionhttp://purl.org/coar/version/c_970fb48d4fbd8a85
person.familyNameFonte
person.givenNamePedro
person.identifier.ciencia-id2410-123D-3385
person.identifier.orcid0000-0002-1115-9282
person.identifier.ridK-3215-2013
person.identifier.scopus-author-id55146900200
project.funder.identifierhttp://doi.org/10.13039/501100001871
project.funder.identifierhttp://doi.org/10.13039/501100001871
project.funder.identifierhttp://doi.org/10.13039/501100001871
project.funder.identifierhttp://doi.org/10.13039/501100001871
project.funder.identifierhttp://doi.org/10.13039/501100001871
project.funder.identifierhttp://doi.org/10.13039/501100001871
project.funder.nameFundação para a Ciência e a Tecnologia
project.funder.nameFundação para a Ciência e a Tecnologia
project.funder.nameFundação para a Ciência e a Tecnologia
project.funder.nameFundação para a Ciência e a Tecnologia
project.funder.nameFundação para a Ciência e a Tecnologia
project.funder.nameFundação para a Ciência e a Tecnologia
relation.isAuthorOfPublicationa5a5c2b2-9112-4bf4-8618-8c2051bbc116
relation.isAuthorOfPublication.latestForDiscoverya5a5c2b2-9112-4bf4-8618-8c2051bbc116
relation.isProjectOfPublicationfafa76a6-2cd2-4a6d-a3c9-772f34d3b91f
relation.isProjectOfPublication15f91d45-e070-47d8-b6b8-efd4de31d9a8
relation.isProjectOfPublication794d4c77-c731-471e-bc96-5a41dcd3d872
relation.isProjectOfPublication2aa82082-d177-45a7-bcfb-53835259cdf7
relation.isProjectOfPublicationb77fb4c4-29d2-40d6-a038-861ad88968d7
relation.isProjectOfPublicationaa89733d-ccad-4fd3-b596-27382f53b0ca
relation.isProjectOfPublication.latestForDiscoveryfafa76a6-2cd2-4a6d-a3c9-772f34d3b91f

Files

Original bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
1-s2.0-S0378517324011530-main.pdf
Size:
9.36 MB
Format:
Adobe Portable Document Format
Download
License bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
license.txt
Size:
3.46 KB
Format:
Item-specific license agreed upon to submission
Description:
Download

Collections

CCM2-Artigos (em revistas ou actas indexadas)